A Phase 2/3 randomized double-blind placebo controlled parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)

Go Back to All Clinical Trials

A Phase 2/3 randomized double-blind placebo controlled parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)

Brief description of study

The purpose of this research study is to test if belimumab is well-tolerated, works well and helps treat interstitial lung disease and other aspects of disease associated with systemic sclerosis such as skin thickening.

Clinical Study Identifier: s23-00873

ClinicalTrials.gov Identifier: NCT05878717

Principal Investigator: David H. Goddard.

Other Investigators: Jennifer Hill, Andres M. Piatti, Lauren E. Wong.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies